Alkol Madde Kullanım Bozukluklarında Farmakolojik Tedaviler
Özet
Alkol, opioid, tütün ve diğer madde kullanım bozukluklarının (AMKB) bütüncül tedavisinde psikososyal yaklaşımların yanı sıra farmakolojik ajanlar da kritik bir rol oynamaktadır. Alkol kullanım bozukluğu tedavisinde, arındırma sürecinde benzodiazepinler tercih edilirken; alkolü bırakma motivasyonu yüksek hastalarda nüks ve aşermeyi önlemek amacıyla disülfiram, akamprosat, naltrekson ve nalmefen gibi FDA onaylı ajanlar kullanılmaktadır. Opioid kullanım bozukluğunda ise Türkiye'de hem arındırma hem idame tedavilerinde onaylı olan ve kötüye kullanımı engellemek için naloksonla kombine edilen buprenorfin ile opioid reseptör antagonistleri olan naltrekson ve nalmefen ön plana çıkmaktadır. Tütün bağımlılığında nikotin replasman tedavilerinin yanı sıra bupropion ve dopamin salınımını düzenleyerek yoksunluğu engelleyen vareniklin yüksek başarı oranlarına sahiptir. Bunlara ek olarak, amfetamin, kokain veya esrar gibi diğer madde kullanım bozukluklarının klinik yönetiminde veya devam eden çalışmalarda antidepresanlar, atipik antipsikotikler, gabapentin, pregabalin, topiramat, baklofen, sodyum oksibat ve kokain bağımlılığında etkili uzun salınımlı vanokserin gibi çeşitli moleküllerden de faydalanılmaktadır. Tüm bu psikofarmakolojik tedaviler, yoksunluk semptomlarını gidermeyi, aşermeyi azaltmayı ve bozulan fizyolojik fonksiyonları normalleştirmeyi amaçlar.
In the holistic treatment of alcohol, opioid, tobacco, and other substance use disorders (SUD), pharmacological agents play a critical role alongside psychosocial approaches. In the treatment of alcohol use disorder, benzodiazepines are preferred during the detoxification process, while FDA-approved agents such as disulfiram, acamprosate, naltrexone, and nalmefene are utilized to prevent relapse and craving in patients with high motivation to quit. In opioid use disorder, buprenorphine—which is combined with naloxone to prevent misuse and is approved for both detoxification and maintenance treatments in Turkey—alongside opioid receptor antagonists like naltrexone and nalmefene stand out. For tobacco dependence, nicotine replacement therapies, bupropion, and varenicline, which prevents withdrawal by regulating dopamine release, exhibit high success rates. Additionally, in the clinical management or ongoing studies of other substance use disorders such as amphetamine, cocaine, or cannabis, various molecules are utilized, including antidepressants, atypical antipsychotics, gabapentin, pregabalin, topiramate, baclofen, sodium oxybate, and long-acting vanoxerine, which is effective in cocaine dependence. All these psychopharmacological treatments aim to alleviate withdrawal symptoms, reduce cravings, and normalize impaired physiological functions.
Referanslar
Mundt AP, Baranyi G, Gabrysch C, Fazel S. Substance use during imprisonment in low-and middle-income countries. Epidemiologic reviews. 2018;40(1):70-81.
Kozak K, Lucatch AM, Lowe DJ, Balodis IM, MacKillop J, George TP. The neurobiology of impulsivity and substance use disorders: implications for treatment. Annals of the New York Academy of Sciences. 2019;1451(1):71-91.
Akbar M, Egli M, Cho Y-E, Song B-J, Noronha A. Medications for alcohol use disorders: An overview. Pharmacology & therapeutics. 2018;185:64-85.
Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815-24.
Burnette EM, Nieto SJ, Grodin EN, Meredith LR, Hurley B, Miotto K, et al. Novel agents for the pharmacological treatment of alcohol use disorder. Drugs. 2022:1-24.
Lohoff FW. Pharmacotherapies and personalized medicine for alcohol use disorder: a review. Pharmacogenomics. 2020;21(15):1117-38.
Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta‐analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2018;113(2):220-37.
Shen WW. Anticraving therapy for alcohol use disorder: A clinical review. Neuropsychopharmacology reports. 2018;38(3):105-16.
Bell J, Strang J. Medication treatment of opioid use disorder. Biological psychiatry. 2020;87(1):82-8.
Shulman M, Wai JM, Nunes EV. Buprenorphine treatment for opioid use disorder: an overview. CNS drugs. 2019;33(6):567-80.
Koehl JL, Zimmerman DE, Bridgeman PJ. Medications for management of opioid use disorder. American Journal of Health-System Pharmacy. 2019;76(15):1097-103.
Blanco-Gandía MC, Rodríguez-Arias M. Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years. European journal of pharmacology. 2018;836:89-101.
Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database of Systematic Reviews. 2016(5).
Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann‐Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. 2019(4).
García-Gómez L, Hernández-Pérez A, Noé-Díaz V, Riesco-Miranda JA, Jiménez-Ruiz C. Smoking cessation treatments: current psychological and pharmacological options. Revista de investigación clínica. 2019;71(1):7-16.
Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.
Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. Journal of medicinal chemistry. 2005;48(10):3474-7.
Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ. 2015;350.
Meyer TE, Taylor LG, Xie S, Graham DJ, Mosholder AD, Williams JR, et al. Neuropsychiatric events in varenicline and nicotine replacement patch users in the M ilitary H ealth S ystem. Addiction. 2013;108(1):203-10.
Stapleton JA, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcliffe M, et al. Varenicline in the routine treatment of tobacco dependence: a pre–post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103(1):146-54.
Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, et al. Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug metabolism and disposition. 2006;34(1):121-30.
Aubin H-J, Bobak A, Britton JR, Oncken C, Billing CB, Gong J, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63(8):717-24.
Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. Cmaj. 2008;179(2):135-44.
Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. The Lancet. 2016;387(10037):2507-20.
Zengin İspir G, Danışman M, Tulacı RG, Özdel K. Emotion Dysregulation and Affective Temperaments in Opioid Use Disorder: the preliminary results of a prospective study. Journal of Addictive Diseases. 2022:1-8.
Pani PP, Trogu E, Vecchi S, Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database of Systematic Reviews. 2011(12).
Nielsen S, Gowing L, Sabioni P, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database of Systematic Reviews. 2019(1).
Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC, et al. Double-blind fluoxetine trial in comorbid MDD–CUD youth and young adults. Drug and alcohol dependence. 2010;112(1-2):39-45.
Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, et al. A randomized double‐blind, placebo‐controlled trial of venlafaxine‐extended release for co‐occurring cannabis dependence and depressive disorders. Addiction. 2013;108(6):1084-94.
Colfax GN, Santos G-M, Das M, Santos DM, Matheson T, Gasper J, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Archives of general psychiatry. 2011;68(11):1168-75.
Anderson AL, Li S-H, Markova D, Holmes TH, Chiang N, Kahn R, et al. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug and alcohol dependence. 2015;150:170-4.
Johnson BA, Ait-Daoud N, Elkashef AM, Smith EV, Kahn R, Vocci F, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. The International Journal of Neuropsychopharmacology. 2008;11(1):1-14.
Zorick T, Sugar CA, Hellemann G, Shoptaw S, London ED. Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. Drug and alcohol dependence. 2011;118(2-3):500-3.
Elkashef A, Kahn R, Yu E, Iturriaga E, Li SH, Anderson A, et al. Topiramate for the treatment of methamphetamine addiction: a multi‐center placebo‐controlled trial. Addiction. 2012;107(7):1297-306.
Ciketic S, Hayatbakhsh MR, Doran CM, Najman JM, McKetin R. A review of psychological and pharmacological treatment options for methamphetamine dependence. Journal of Substance Use. 2012;17(4):363-83.
Indave BI, Minozzi S, Pani PP, Amato L. Antipsychotic medications for cocaine dependence. Cochrane Database of Systematic Reviews. 2016(3).
Meredith CW, Jaffe C, Yanasak E, Cherrier M, Saxon AJ. An open-label pilot study of risperidone in the treatment of methamphetamine dependence. Journal of psychoactive drugs. 2007;39(2):167-72.
Meredith CW, Jaffe C, Cherrier M, Robinson JP, Malte CA, Yanasak EV, et al. Open trial of injectable risperidone for methamphetamine dependence. Journal of Addiction Medicine. 2009;3(2):55-65.
Sherman BJ, McRae‐Clark AL. Treatment of cannabis use disorder: current science and future outlook. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2016;36(5):511-35.
Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012;37(7):1689-98.
Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin—results from the Swedish spontaneous adverse drug reaction reporting system. European journal of clinical pharmacology. 2010;66(9):947-53.
Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS drugs. 2014;28(6):491-6.
Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403-26.
Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D. Pharmacotherapy for cocaine use disorder—a systematic review and meta-analysis. Journal of general internal medicine. 2019;34(12):2858-73.
Ahmed S, Bachu R, Kotapati P, Adnan M, Ahmed R, Farooq U, et al. Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review. Frontiers in psychiatry. 2019;10:228.
Singh M, Keer D, Klimas J, Wood E, Werb D. Topiramate for cocaine dependence: a systematic review and meta‐analysis of randomized controlled trials. Addiction. 2016;111(8):1337-46.
Rezaei F, Ghaderi E, Mardani R, Hamidi S, Hassanzadeh K. Topiramate for the management of methamphetamine dependence: a pilot randomized, double‐blind, placebo‐controlled trial. Fundamental & clinical pharmacology. 2016;30(3):282-9.
Heinzerling KG, Shoptaw S, Peck JA, Yang X, Liu J, Roll J, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug and alcohol dependence. 2006;85(3):177-84.
Mannucci C, Pichini S, Spagnolo EV, Calapai F, Gangemi S, Navarra M, et al. Sodium oxybate therapy for alcohol withdrawal syndrome and keeping of alcohol abstinence. Current Drug Metabolism. 2018;19(13):1056-64.
Rothman RB, Mele A, Reid AA, Akunne HC, Greig N, Thurkauf A, et al. GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacology Biochemistry and Behavior. 1991;40(2):387-97.
Kadric S, Mohler H, Kallioniemi O, Altmann KH. A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of long-acting injectable formulation of vanoxerine (Vanoxerine Consta 394.2 mg) for cocaine relapse prevention. World Journal of Neuroscience. 2019;9(03):113.
